BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 25070294)

  • 21. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma.
    Agrawal S; Kane JM; Guadagnolo BA; Kraybill WG; Ballo MT
    Cancer; 2009 Dec; 115(24):5836-44. PubMed ID: 19701906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elective, therapeutic, and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998.
    Fisher SR
    Laryngoscope; 2002 Jan; 112(1):99-110. PubMed ID: 11802046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of BRAF mutations in primary melanoma growth rate and survival.
    Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
    Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
    Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
    Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
    Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon AM; Meshcheryakov A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; van Akkooi ACJ; Krepler C; Ibrahim N; Marreaud S; Kicinski M; Suciu S; Robert C
    J Clin Oncol; 2020 Nov; 38(33):3925-3936. PubMed ID: 32946353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF mutation-positive folliculotropic metastatic melanoma.
    Brick KE; Halling KC; Khan YK; Peters MS
    Am J Dermatopathol; 2013 Jul; 35(5):609-12. PubMed ID: 23715079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
    Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
    Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma.
    Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G
    Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
    Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
    Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
    Larsen AC
    Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.
    van Akkooi AC; Bouwhuis MG; de Wilt JH; Kliffen M; Schmitz PI; Eggermont AM
    Br J Surg; 2007 Oct; 94(10):1293-9. PubMed ID: 17702089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for nodal recurrence after lymphadenectomy for melanoma.
    Pidhorecky I; Lee RJ; Proulx G; Kollmorgen DR; Jia C; Driscoll DL; Kraybill WG; Gibbs JF
    Ann Surg Oncol; 2001 Mar; 8(2):109-15. PubMed ID: 11258774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
    Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
    Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.